Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 159

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 11
Chunk 159
---
 prorated for partial years of service and paid quarterly in arrears. The Company did not issue the annual stock option awards in January 2025 as the Board of Directors intends to update the Compensation Policy.

The following table sets forth information with respect to compensation earned by or awarded to each of our non-employee directors who served on the Board of Directors during the fiscal year ended December 31, 2024:

Name  Fees Earned or Paid in Cash ($)  Option Awards ($)(1)  All Other Compensation ($) Total ($) Anthony DiGiandomenico  40,000   954     40,954 Michael Harsh  40,000   954     40,954  Louis Basenese  40,000   954     40,954 

(1) In January 2024, members of the Board were awarded their annual option grant to purchase 600 shares with a per share exercise price of $1.59.  This grant was subject to adjustment due to the Company’s August 2024 Reverse Stock Split and the November 2024 Reverse Stock Split.  After adjustment, this grant is for 0.3429 shares with a per share exercise price of $2,782.50.  The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see Notes 2 and 8 to the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The following table shows the number of shares subject to outstanding option awards held by each non-employee director as of December 31, 2024:

 62Table of Contents

Name Shares Subject to Outstanding Option Awards  Louis Basenese  7 Anthony DiGiandomenico  11 Michael Harsh  11 

ENDRA Policy Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

We have no practice or policy of coordinating or timing the release of the Company information around the grant date of our equity incentive awards, and we have not timed the disclosure of material non-public information for the purposes of affecting the value of executive compensation. During fiscal 2024, we did not grant any stock options (or similar awards) to any of our